Presentation at BioContact Québec 2008


    MONTREAL, Sept. 25 /CNW Telbec/ - Haemacure Corporation (TSX:HAE), a
specialty bio-therapeutics company developing high-value human proteins,
announces that Mr. Joseph Galli, Chairman and Chief Executive Officer, will be
presenting at BioContact Québec 2008. Mr. Galli will present a corporate
progress report, including an update on the Company's lead product candidate,
Hemaseel(R)HMN (fibrin sealant). The Haemacure presentation is scheduled to
begin at 16:30 p.m. local time on Wednesday, October 1st in the Bellevue Room
at the Château Frontenac in Quebec City.
    Information about BioContact Québec 2008 is available at

    About Haemacure

    Haemacure Corporation is a specialty biotherapeutics company developing
high-value human plasma-derived protein products for commercialization.
Haemacure's research and development effort is driven by its proprietary
plasma protein extraction technology to develop next-generation products,
including surgical hemostats. Haemacure's lead product candidate,
Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/Phase
III clinical trials during the first half of 2009. Haemacure's second product
candidate is thrombin, a component of its fibrin sealant, now in preclinical
stage. Follow-on development will focus on the use of its fibrin sealant in
adhesion prevention, aesthetics, combination with biomaterials, drug delivery,
regenerative medicine, skin graft fixation for burn injuries and wound
management. Haemacure has discovered eleven additional specialty proteins and
enzymes in one if its two plasma fractions and seeks to advance these proteins
and enzymes through partnerships with pharmaceutical and biotechnology
companies. Haemacure is headquartered in Montreal, Quebec and operates offices
in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is
traded under stock symbol HAE on the TSX.

    Forward-looking Statements

    Certain of the statements contained in this news release are
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown. Some examples of known risks are: the impact
of general economic conditions, general conditions in the biotech industry,
changes in the regulatory environment in the jurisdictions in which Haemacure
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation or otherwise. Consequently,
actual future results may differ materially from the anticipated results
expressed in the forward-looking statements. Haemacure disclaims any intention
or obligation to update these statements.

For further information:

For further information: Haemacure Corporation: Joseph Galli, Chairman
and CEO, (514) 990-7074,,; Gilles
Lemieux, Secretary, (514) 282-3350 ext. 22,,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890